Neprilysin inhibitors

Patent metadata

Field	Value
Publication number	US-11261197-B2
Application number	US-202016947214-A
Country	US
Kind code	B2
Filing date	Jul 23, 2020
Priority date	Dec 15, 2010
Publication date	Mar 1, 2022
Grant date	Mar 1, 2022

Abstract

In one aspect, the invention relates to compounds having the formula:where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

First claim

What is claimed is:

1. A method of treating a disease mediated at least in part by neprilysin in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:
le is selected from —OR 7 and —NR 8 R 9 ;
R 2 is selected from H and —P(O)(OH) 2 ;
X is —C 1-9 heteroaryl;
R 3 is absent or is selected from H; halo; —C 0-5 alkylene-OH; —NH 2 ; —C 1-6 alkyl; —CF 3 ; —C 3-7 cycloalkyl; —C 0-2 alkylene-O—C 1-6 alkyl; —C(O)R 20 ; —C 0-1 alkylene-COOR 21 ; —C(O)NR 22 R 23 ; —NHC(O)R 24 ; ═O; —NO 2 ; —C(CH 3 )═N(OH); phenyl, optionally substituted with one or two groups independently selected from halo, —OH, —CF 3 , —OCH 3 , —NHC(O)CH 3 , and phenyl; naphthalenyl; pyridinyl; pyrazinyl; pyrazolyl, optionally substituted with methyl; thiophenyl, optionally substituted with methyl or halo; furanyl; and —CH 2 -morpholinyl; wherein R 3 , when present, is attached to a carbon atom;
R 4 is absent or is selected from H; —OH; —C 1-6 alkyl; —C 1-2 alkylene-COOR 35 ; —CH 2 OC(O)CH(R 36 )NH 2 ; —OCH 2 OC(O)CH(R 36 )NH 2 ; —OCH 2 OC(O)CH 3 ; —CH 2 OP(O)(OH) 2 ; —CH 2 CH(OH)CH 2 OH; —CH[CH(CH 3 ) 2 ]—NHC(O)O—C 1-6 alkyl; pyridinyl; and phenyl or benzyl, each of which is optionally substituted with one or more groups selected from halo, —COOR 35 , —OCH 3 , —OCF 3 , and —SCF 3 ; wherein R 4 , when present, is attached to a carbon or nitrogen atom;
a is 0 or 1;
R 5 is selected from halo, —CH 3 , —CF 3 , and —CN;
b is 0 or an integer from 1 to 3;
each R 6 is independently selected from halo, —OH, —CH 3 , —OCH 3 , and —CF 3 ;
R 7 is selected from H, —C 1-8 alkyl, —C 1-3 alkylene-C 6-10 aryl, —C 1-3 alkylene-C 1-9 heteroaryl, —C 3-7 cycloalkyl, —[(CH 2 ) 2 O] 1-3 CH 3 , —C 1-6 alkylene-OC(O)R 10 , —C 1-6 alkylene-NR 12 R 13 , —C 1-6 alkylene-C(O)R 31 , —C 0-6 alkylenemorpholinyl, —C 1-6 alkylene-SO 2 -C 1-6 alkyl,

R 10 is selected from —C 1-6 alkyl, —O—C 1-6 alkyl, —C 3-7 cycloalkyl, —O—C 3-7 cycloalkyl, phenyl, —O-phenyl, —NR 12 R 13 , —CH[CH(CH 3 ) 2 ]—NH 2 , —CH[CH(CH 3 ) 2 ]—NHC(O)O—C 1-6 alkyl, and —CH(NH 2 )CH 2 COOCH 3 ;
R 12 and R 13 are independently selected from H, —C 1-6 alkyl, and benzyl; or
R 12 and R 13 are taken together as —(CH 2 ) 3-6 —, —C(O)—(CH 2 ) 3 —, or —(CH 2 ) 2 O(CH 2 ) 2 —;
R 31 is selected from —O—C 1-6 alkyl, —O-benzyl, and —NR 12 R 13 ;
R 32 is selected from —C 1-6 alkyl and —C 0-6 alkylene-C 6-10 aryl;
R 8 is selected from H, —OH, —OC(O)R 14 , —CH 2 COOH, —O-benzyl, -pyridyl, and —OC(S)NR 15 R 16 ;
R 14 is selected from H, —C 1-6 alkyl, —C 6-10 aryl, —OCH 2 —C 6-10 aryl, —CH 2 O—C 6-10 aryl, and —NR 15 R 16 ;
R 15 and R 16 are independently selected from H and —C 1-4 alkyl;
R 9 is selected from H, —C 1-6 alkyl, and —C(O)—R 17 ;
R 17 is selected from H, —C 1-6 alkyl, —C 3-7 cycloalkyl, —C 6-10 aryl, and —C 1-9 heteroaryl;
R 20 is selected from H and —C 1-6 alkyl;
R 21 and R 35 are independently selected from H, —C 1-6 alkyl, —C 1-3 alkylene-C 6-10 aryl, —C 1-3 alkylene-C 1-9 heteroaryl, —C 3-7 cycloalkyl, —[(CH 2 ) 2 O] 1-3 CH 3 , —C 1-6 alkylene-OC(O)R 25 , —C 1-6 alkylene-NR 27 R 28 , —C 1-6 alkylene-C(O)R 33 , —C 0-6 alkylenemorpholinyl, —C 1-6 alkylene-SO 2 -C 1-6 alkyl,

R 25 is selected from —C 1-6 alkyl, —O—C 1-6 alkyl, —C 3-7 cycloalkyl, —O—C 3-7 cycloalkyl, phenyl, —O-phenyl, —NR 27 R 28 , —CH[CH(CH 3 ) 2 ]—NH 2 , —CH[CH(CH 3 ) 2 ]—NHC(O)O—C 1-6 alkyl, and —CH(NH 2 )CH 2 COOCH 3 ;
R 27 and R 28 are independently selected from H, —C 1-6 alkyl, and benzyl; or
R 27 and R 28 are taken together as —(CH 2 ) 3-6 —, —C(O)—(CH 2 ) 3 —, or —(CH 2 ) 2 O(CH 2 ) 2 —;
R 33 is selected from —O—C 1-6 alkyl, —O-benzyl, and —NR 27 R 28 ;
R 34 is selected from —C 1-6 alkyl and —C 0-6 alkylene-C 6-10 aryl;
R 22 and R 23 are independently selected from H, —C 1-6 alkyl, —CH 2 COOH, —(CH 2 ) 2 OH, —(CH 2 ) 2 OCH 3 , —(CH 2 ) 2 SO 2 NH 2 , —(CH 2 ) 2 N(CH 3 ) 2 , —C 0-1 alkylene-C 3-7 cycloalkyl, and —(CH 2 ) 2 -imidazolyl; or
R 22 and R 23 are taken together to form a saturated or partially unsaturated —C 3-5 heterocycle, optionally substituted with halo, —OH, —COOH, or —CONH 2 ;
R 24 is selected from —C 1-6 alkyl; —C 0-1 alkylene-O—C 1-6 alkyl; phenyl, optionally substituted with halo or —OCH 3 ; and —C 1-9 heteroaryl; and
R 36 is selected from H, —CH(CH 3 ) 2 , phenyl, and benzyl;
wherein each alkyl group in R 1 , R 3 , and R 4 is optionally substituted with 1 to 8 fluoro atoms; and
wherein the methylene linker on the biphenyl is optionally substituted with one or two —C 1-6 alkyl groups or cyclopropyl.

2. The method of claim 1 , wherein the disease is selected from hypertension, heart failure, and renal disease.

3. The method of claim 1 , further comprising administering a therapeutic agent selected from an AT 1 receptor antagonist, an angiotensin-converting enzyme inhibitor, a phosphodiesterase inhibitor, a renin inhibitor, and a diuretic, or a combination thereof.

4. The method of claim 1 , further comprising administering an AT 1 receptor antagonist, wherein the AT 1 receptor antagonist is selected from abitesartan, azilsartan, azilsartan medoxomil, benzyllosartan, candesartan, candesartan cilexetil, elisartan, embusartan, enoltasosartan, eprosartan, EXP3174, fonsartan, forasartan, glycyllosartan, irbesartan, isoteoline, losartan, milfasartan, olmesartan, olmesartan medoxomil, opomisartan, pratosartan, ripisartan, saprisartan, saralasin, sarmesin, TAK-591, tasosartan, telmisartan, valsartan, and zolasartan.

5. The method of claim 1 , wherein R 1 is —OR 7 ; and R 7 is selected from H and —C 1-8 alkyl.

6. The method of claim 1 , wherein R 2 is H.

7. The method of claim 1 , wherein X is selected from oxazole and isoxazole.

8. The method of claim 1 , wherein R 3 is selected from H, —C 0-5 alkylene-OH, —C 1-6 alkyl, and —C 0-2 alkylene-O—C 1-6 alkyl; and R 4 is H.

9. The method of claim 1 , wherein a is 0; b is 0, 1 or 2; and each R 6 is independently selected from halo.

10. The method of claim 1 , wherein R 1 is —OR 7 ; R 7 is selected from H and —C 1-8 alkyl; R 2 is H; X is selected from oxazole and isoxazole; R 3 is selected from H, —C 0-5 alkylene-OH, —C 1-6 alkyl, and —C 0-2 alkylene-O—C 1-6 alkyl; R 4 is H; a is 0; b is 0, 1 or 2; and each R 6 is independently selected from halo.

11. The method of claim 1 , wherein the compound of Formula (I) is a compound of Formula (Ia):

or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 , wherein R 1 is —OR 7 ; R 7 is selected from H and —C 1-8 alkyl; R 2 is H; X is selected from oxazole and isoxazole; R 3 is selected from H, —C 0-5 alkylene-OH, —C 1-6 alkyl, and —C 0-2 alkylene-O—C 1-6 alkyl; R 4 is H; a is 0; b is 0, 1 or 2; and each R 6 is independently selected from halo.

13. The method of claim 1 , wherein the compound of Formula (I) is a compound of the formula:

or a pharmaceutically acc

Assignees

• Theravance Biopharma R&D Ip Llc

Inventors

• Gendron Roland
• Fleury Melissa
• Hughes Adam D

Classifications

• C07D277/46

  by carboxylic acids, or sulfur or nitrogen analogues thereof · CPC title

• A61P1/12

  Antidiarrhoeals · CPC title

• C07D241/24

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• A61K31/422

  not condensed and containing further heterocyclic rings · CPC title

• C07D213/81 Primary

  Amides; Imides · CPC title